Compare GSK plc (GSK) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Harley-Davidson Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Harley-Davidson Inc trades at $27.17 (market cap $2.78B). The key difference: GSK plc is far larger — about 36.9× Harley-Davidson Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | HOG | |
|---|---|---|
Market Cap | $102.60B | $2.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $31.03 |
52-Week Low | $38.22 | $17.19 |
Enterprise Value | $123.04B | $3.19B |
Dividend Yield | 3.57% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Harley-Davidson (HOG) trades at $25.98, down 0.46% on the day, with a bullish technical signal from moving averages but mixed oscillators. Recent Q2 2026 earnings beat estimates at $0.75 per share versus $0.645 expected, though revenue declined year-over-year. The company raised full-year guidance, citing strong North American retail sales and cost-cutting initiatives under its 'Back to the Bricks' strategy, while returning Revolution Max engine production to the U.S.
The stock presents a value opportunity with a low P/E of 14.84 and P/S of 0.72, but faces headwinds from declining revenue and net margins. Analyst consensus is mixed with a $26 price target near the current price, indicating limited near-term upside. Key risks include competitive pressures, raw material cost inflation, and execution of the turnaround plan amid weakening profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
